Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.00 |
|---|---|
| High | 4.81 |
| Low | 4.81 |
| Bid | -- |
| Offer | -- |
| Previous close | 4.81 |
| Average volume | -- |
|---|---|
| Shares outstanding | 18.29m |
| Free float | 17.97m |
| P/E (TTM) | -- |
| Market cap | 9.93m USD |
| EPS (TTM) | -2.98 USD |
Data delayed at least 15 minutes, as of Apr 15 2024 07:11 BST.
More ▼
Announcements
- Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
- Lifeward Appoints Bob Marshall as Chairman of the Board
- Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates
- Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval
- UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton
- Lifeward Ltd. Reports Third Quarter 2025 Financial Results
- Lifeward to Report Third Quarter Financial Results on November 14, 2025
- First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton
- Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton
- Lifeward Ltd. Reports Second Quarter 2025 Financial Results
More ▼
